Back to homepage

Psychiatry

Antidepressant efficacy and side-effect burden: a quick guide for clinicians

Authors: Daniel Santarsieri, Thomas L Schwartz

Prescribing of antidepressant treatment (ADT) for major depressive disorder (MDD) has increased substantially over the last two decades. In this paper, the authors discuss the evidence that supports the use of ADT based on FDA approvals, data from randomized controlled trials or meta-analyses and where these are not available, the authors discuss and apply theoretical pharmacodynamic principles to help guide treatment choice in MDD.

More

Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder

Authors: Molly R Belkin, Thomas L Schwartz

Posttraumatic stress disorder (PTSD) is thought to be related to a hyperactive sympathetic nervous system. Sometimes, use of the US Food and Drug Administration (FDA)-approved medications for PTSD, the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine, may not lead to full remission and symptoms of hyperarousal may persist. In this article the authors review the literature on the alpha-2 receptor agonists clonidine and guanfacine for the treatment of PTSD and conclude that while the evidence base is limited, these agents might be considered useful when SSRIs fail in patients with PTSD.

More

Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome

Authors: Pavel Gershokovich, Kishor M Wasan, Charles Ribeyre, Fady Ibrahim, John H McNeill

Benzodiazepines (BDZ) are the drugs of choice to prevent the symptoms of alcohol withdrawal syndrome (AWS). Differences in treatment regimens, the choice of BDZ, as well as the presence of liver cirrhosis can substantially alter the exposure of patients to drugs used for AWS treatment so patients should be carefully monitored.

More

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

Authors: James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mary Anne Dellva, Qi Zhang, Peng Liu, Mark Bangs, Jonna Ahl, Celine Goldberger

This analysis confirms that the tolerability and safety profile of edivoxetine as adjunctive treatment to SSRI antidepressants was consistent with its norepinephrine reuptake inhibitor mechanism of action, and was comparable with edivoxetine monotherapy treatment in patients with major depressive disorder.

More

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Authors: Siddhesh A Kamat, Steve Offord, John Docherty, Jay Lin, Anna Eramo, Ross A Baker, Benjamin Gutierrez, Craig Karson

The results from this large cohort study provided naturalistic real-world evidence of the utility of LAIs in patients with schizophrenia and suggest that these agents may help to reduce the risk of relapse across all age groups, especially among younger patients.

More